Fertin Pharma

Fertin Pharma, established in 2001, is a contract development and manufacturing organization (CDMO) in the Pharmaceutical and Healthcare sectors. The company specializes in research, development, and production of solid oral dosage systems, including gums, pouches, and liquefiable tablets for active ingredient delivery. Its expertise covers pharmaceutical and nutraceutical applications, with a focus on nicotine products and nicotine replacement therapy (NRT). Fertin Pharma's specialized formulation and manufacturing capabilities position it as a key partner for advanced delivery solutions.

Operating with 500-1,000 employees across 4 locations, Fertin Pharma possesses significant operational capacity. Its manufacturing capabilities support a wide array of functional formats, ensuring precise dosage and ingredient stability for pharmaceutical and medical needs. The company leverages advanced technologies for product creation. To learn more about the team driving these specialized operations, explore Meet Fertin Pharma's team. This dedicated team and focus on specialized production underpin its role as a CDMO.

Fertin Pharma's strategic focus on specialized oral delivery systems, particularly for active ingredients like nicotine, carves a niche in the pharmaceutical and healthcare market. While specific competitor data is not provided, the company's established presence and specialized product portfolio suggest a competitive positioning. Its operations, headquartered in Vejle, Denmark, serve a global clientele, as indicated by its diverse hashtag presence. The company's revenue of $286.9M reflects its significant market engagement and operational scale in delivering advanced oral dosage forms.